Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly ups growth prediction

Eli Lilly ups growth prediction

13th December 2005

Eli Lilly has told Wall Street investors that it is positioned to deliver sustained growth in 2006.

The company announced that sales next year are expected to increase to more than $15 billion, coming from better performance from the drugs Zyprexa and Cymbalta.

Lilly president and chief operating officer Dr John Lechleiter said: “We are somewhat encouraged by Zyprexa’s recent US performance where the erosion of Zyprexa prescriptions slowed in recent months.

“Our goals are to further stabilize US Zyprexa sales and sustain modest growth on a global basis.”

He also described that while there was an overall flat antidepressant market in 2005, Cymbalta has led all branded and promoted products in share-of-market growth during this period.

Cymbalta has also performed well in Europe and had the company’s best ever anti-depressant launch in Germany.

Lilly’s chief executive Sidney Taurel told investors the company’s situation was also buoyed by the fact there were no major drugs in line to lose their patent protection in the next five years and nine products launched since 2001 will produce increased revenue.

He added: “We continue to expand into new markets such as our recent submissions of Byetta in Europe for type 2 diabetes, Cialis in Japan for erectile dysfunction, and Cymbalta in key European markets.”

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.